Tenet Medicines, Inc.

Completes Transition to Immune-Mediated Disease Focused Company Highlights Additional Data from Phase 1b Primary Membranous Nephropathy (pMN) Study with plans to Advance to Late Phase Development in 2025 Outlines Plans for Clinical Trials in Systemic Lupus Erythematosus (SLE) and Immune Thrombocytopenia (ITP) with First Patients Dosed Targeted for 1H25 Cash runway through 2027 Expected to Enable Delivery of Key Value Inflection Points Virtual Investor Event to be Held at 12:00 p.m. ET Today WELLESLEY HILLS, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), will be hosting a virtual investor event, today, October 15, 2024, from 12:00 p.m. to 2:00 p.m. ET. The event will feature members of Climb Bio’s management team who will provide an update on the Company’s development strategy for budoprutug, an anti-CD19 monoclonal antibody with potential to treat a broad range of B-cell mediated diseases. The event will also feature Dr. Frank Cortazar, Director of the New York Vasculitis and Glomerular Center and Chief of Clinical Research at St. Peter's Health Partners, who was the primary investigator in the Phase 1b trial of budoprutug in pMN. Dr. Cortazar will present additional data from the completed pMN trial and share clinical data from a single patient with Minimal Change Disease (MCD) treated with budoprutug. “Our mission at Climb Bio is to develop better treatments for the approximately 50 million patients in the U.S. and many more globally living with immune-mediated diseases,” said Aoife Brennan, President and CEO of Climb Bio. “We are off to a great start with some world class talent and a cornerstone asset, budoprutug. We believe CD19 is the optimal target for B-cell mediated diseases and that an antibody is the modality with the broadest potential to help patients. We are thrilled today to share our development strategy and promising preclinical and clinical data that underscore our enthusiasm for budoprutug’s potential.” Dr. Cortazar added, “I know firsthand the challenges of managing patients with pMN and the need for new treatment options. The patients in the pMN trial demonstrated high rates of complete clinical remission, as well as rapid reductions in B-cells and anti-PLA2R antibodies, two key biomarkers for pMN. These data potentially support a significant advancement in our fight against this challenging condition, and I am hopeful to continue to help advance this innovative therapy for those in need.” Event Highlights Rational and data driven clinical development strategy The Company’s strategic approach to developing budoprutug will consider indications across three opportunity sets, including; IgG4-mediated diseases, such as pMN;Diseases caused by IgG1-3 that impact a single organ system, such as ITP; andComplex systemic diseases, such as SLE. Budoprutug is a differentiated anti-CD19 monoclonal antibody with potential for potent B-cell depletion The Company will share data supporting budoprutug’s potential for deep and durable depletion of both peripheral and tissue-resident B-cells in patients with immune-mediated diseases In a transgenic mouse model expressing human CD19, budoprutug achieved dose-dependent B-cell depletion in bone marrow, lymph nodes, and spleen.Doses as low as 100 mg induced B-cell depletion to undetectable levels in pMN patients treated with budoprutug. Continued advancement of subcutaneous formulation of budoprutug Budoprutug has been successfully formulated above 175 mg/ml while maintaining low viscosity, creating an opportunity to pursue a subcutaneous dosing form that potentially features a low volume injection.The Company plans to continue to advance the subcutaneous formulation clinical program, with non-clinical data expected in the first half of 2025. Additional promising Phase 1b Study Results in pMN Dr. Frank Cortazar, Director of the New York Nephrology Vasculitis and Glomerular Center, will present additional data from the Phase 1b study of budoprutug in patients with pMN.The study demonstrated the following for the 5 patients who received all 4 doses of budoprutug: Complete remission of proteinuria achieved by 3/5 (60%) of patients.Rapid and significant reductions in anti-PLA2R autoantibodies, a key driver of pMN, with serological remission occurring in the 3 patients that were PLA2R positive at baseline.Complete and sustained B-cell depletion was observed in all patients, with undetectable levels of B-cells occurring after just two doses of study drug as low as 100 mg.Budoprutug was generally well-tolerated, with no reported drug-related serious adverse events. Full data from this study will be presented in a poster presentation on October 24th at the American Society of Nephrology’s Kidney Week 2024 being held in San Diego, CA.Dr. Cortazar will also share data from a single patient trial for MCD showing the MCD patient was able to fully taper steroid and remains in complete remission 18 months following final administration of budoprutug, given as 4 doses over 6 months, 600mg cumulative dose. Initiation of Phase 1b clinical trial in SLE planned for the first half of 2025, subject to regulatory clearance SLE is a complex, chronic systemic disease opportunity affecting multiple organ systems, leading to significant morbidity and mortality that affects approximately 200,000 to 300,000 people in the U.S.Design of Phase 1b trial in SLE: An open-label trial in patients with active lupus is planned.Endpoints will include clinical response, decline in pathogenic autoantibodies, and assessment of B-cell subsets upon recovery.The trial will utilize informative serum biomarkers to accelerate proof-of-concept, optimize dosing, and benchmark against other B-cell depleting therapies. Initiation of Phase 2 clinical trial in ITP planned for the first half of 2025, subject to regulatory clearance ITP is an IgG 1-3 immune-mediated disorder affecting an estimated 60,000 adults in the U.S. and where there is compelling proof-of-concept validating the clinical rationale for using B-cell depletion therapies.Design of Phase 2 trial in ITP: Single-arm, open-label study in adult patients with chronic ITP is planned.Primary endpoint will measure platelet improvement along with other disease parameters.A unique "treat-to-target" approach is included in the study protocol to allow for personalized redosing based on individual patient needs. Corporate Update and Upcoming Milestones As of September 30, 2024, the Company had cash, cash equivalents and marketable securities of approximately $218 million, which is expected to fund operations through 2027.Initiation of clinical trials in SLE and ITP with first patients dosed targeted for the first half of 2025, subject to regulatory clearance.Advancement of subcutaneous formulation clinical program, with non-clinical data expected in the first half of 2025.Advancement of pMN clinical program to late phase development expected in 2025. Event DetailsClimb Bio, Inc. will host its virtual investor event, today, October 15, 2024, from 12:00 p.m. to 2:00 p.m. ET. To attend the virtual event, please register here. The live webcast of the event, as well as a replay, will be available under "Events and Presentations" in the Investors section of the Company's website: climbbio.com. About Climb Bio, Inc. Climb Bio, Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. For more information, please visit climbbio.com. Forward-Looking StatementsThis press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding: future expectations, plans and prospects for Climb Bio; the anticipated benefits of the acquisition of Tenet Medicines, Inc.; expectations regarding budoprutug’s therapeutic benefits, clinical potential and clinical development; the trial design for the planned clinical trials of budoprutug; plans to optimize the administration of budoprutug; the anticipated timelines for initiating clinical trials of budoprutug; the sufficiency of Climb Bio’s cash resources for the period anticipated and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” “will,” “working” and similar expressions. Forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. Climb Bio may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. These risks and uncertainties include, but are not limited to, important risks and uncertainties associated with: the ability of Climb Bio to timely and successfully achieve or recognize the anticipated benefits of its acquisition of Tenet Medicines, Inc.; changes in applicable laws or regulation; the possibility that Climb Bio may be adversely affected by other economic, business and/or competitive factors; Climb Bio’s ability to advance budoprutug on the timelines expected or at all and to obtain and maintain necessary approvals from the U.S. Food and Drug Administration and other regulatory authorities; obtaining and maintaining the necessary approvals from investigational review boards at clinical trial sites and independent data safety monitoring boards; replicating in clinical trials positive results found in early-stage clinical trials of budoprutug; competing successfully with other companies that are seeking to develop treatments for systemic lupus erythematosus, immune thrombocytopenia and membranous nephropathy and other immune-mediated diseases; maintaining or protecting intellectual property rights related to budoprutug and/or its other product candidates; managing expenses; and raising the substantial additional capital needed, on the timeline necessary, to continue development of budoprutug and any other product candidates Climb Bio may develop. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Climb Bio’s actual results to differ materially from those contained in the forward-looking statements, see the “Risk Factors” section, as well as discussions of potential risks, uncertainties and other important factors, in Climb Bio’s most recent filings with the U.S. Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Climb Bio’s views as of the date hereof and should not be relied upon as representing Climb Bio’s views as of any date subsequent to the date hereof. Climb Bio anticipates that subsequent events and developments will cause Climb Bio’s views to change. However, while Climb Bio may elect to update these forward-looking statements at some point in the future, Climb Bio specifically disclaims any obligation to do so, except as required by law. InvestorsChris Brinzey ICR Westwickechris.brinzey@westwicke.com 339-970-2843 MediaJon YuICR Westwickejon.yu@westwicke.com475-395-5375

作者｜零星 自身免疫疾病（AID）是指机体免疫系统对自身组织或细胞的攻击所引发的一类疾病，包括类风湿性关节炎、系统性红斑狼疮、炎性肠病等。 随着科学研究的深入发展和治疗方法的创新，自免并购活动在过去几十年中不断增加，推动了行业的快速发展。本文简要梳理！   01   自免并购的早期阶段: 20世纪末期 20世纪末期，各大生物技术和制药公司开始认识到自身免疫疾病治疗市场的潜力，虽然这一时期行业内相关的并购活动相对较少，但仍为后续蓬勃发展的市场以及并购活动的发展奠定了一定基础。 这一时期重要的并购案包括： 53亿美元：罗氏收购Syntex（1994） 罗氏（Roche）以53亿美元收购美国生物技术公司Syntex，帮助罗氏加强了在风湿性关节炎和其他自免疾病治疗领域的产品组合； 图2：《芝加哥论坛报》报道罗氏收购Syntex的新闻 820亿美元：辉瑞收购Warner-Lambert（1999） 辉瑞（Pfizer）以约820亿美元的价格收购了Warner-Lambert。这次并购虽然主要是为了取得著名的降胆固醇药物立普妥（Lipitor），但也极大增强了辉瑞在自身免疫疾病药物开发方面的实力。 图3：《华盛顿邮报》辉瑞收购Warner-Lambert的新闻 赛诺菲-安万特（Sanofi-Aventis）成立（1999） 1999年，赛诺菲（Sanofi）和霍诺（Hoechst Marion Roussel）合并成立了赛诺菲-安万特（Sanofi-Aventis），这次合并使赛诺菲在自身免疫疾病治疗领域拥有更强的研发能力和市场份额。 图4：赛诺菲（Sanofi）和霍诺（Hoechst Marion Roussel）的相关报道 160亿美元：Amgen收购Immunex（2001） 在这一时期，还有一个典型的收购案例，2001年，Amgen以160亿美元收购Immunex，获取了其重磅药物Enbrel（依那西普）。Enbrel是一种抗肿瘤坏死因子（TNF）药物，主要用于治疗类风湿性关节炎和其他自身免疫疾病。这次收购不仅使得Amgen在免疫疾病治疗领域的地位显著提升，也为其带来了可观的财务回报 。 图5：Nature Technology网站对Amgen收购Immunex的报道 图6：Amgen官网新闻 自身免疫领域（自免领域）的并购案反映了生物技术和制药行业的整合趋势这些并购案不仅加速了自身免疫疾病治疗药物的开发和上市，也推动了生物技术和制药行业的整合和创新。通过并购，这些公司能够获取更多的资源、技术和市场，进而提升其竞争力和市场地位。   02   自免并购的汹涌浪潮：2015~2020 进入21世纪第二个十年，自身免疫疾病治疗市场迅速扩展，生物技术的进步和新疗法的开发推动了大量并购交易。 这十年间，若干生物技术和制药公司纷纷加入并购浪潮，自免领域并购案例如雨后春笋般涌现，时常占据医药行业新闻头条，引起国内外众多关注。 210亿美元：AbbVie收购Pharmacyclics（2015） 2015年AbbVie以210亿美元的价格收购了Pharmacyclics，通过本次收购，Abbvie获得了Pharmacyclics的于治疗多种血液系统疾病的药物Imbruvica（依鲁替尼）。虽然Imbruvica主要用于癌症治疗，但其研究成果为自身免疫疾病治疗提供了新的思路，并增强了AbbVie在免疫学领域的研发能力 。 图7：AbbVie官网并购内容 72亿美元：Celgene收购Receptos（2015） Celgene以72亿美元收购Receptos，主要是为了其在研药物Ozanimod，这是一种用于治疗多发性硬化症和溃疡性结肠炎的S1P受体调节剂。Ozanimod的开发成功使Celgene在自身免疫疾病治疗领域的布局更加完善 。 图8：Market Screen对此次并购的相关报道 25亿美元：Sanofi收购Synthorx（2019） 2019年，Sanofi收购Synthorx。Sanofi以25亿美元收购了Synthorx，获取其以工程化IL-2为基础的免疫治疗技术。Synthorx的技术平台旨在增强免疫系统的选择性，开发新型治疗方法来治疗癌症和自身免疫疾病，进一步拓展了Sanofi在免疫治疗领域的产品线 。 图9：Sanofi官网对此次并购的说明   03   自免并购继续升温：近五年情况 再把视野转向2020年至今，我们可以直观地看到，在过去的几年中，自身免疫领域的并购活动继续升温，主要驱动力包括对创新疗法的需求、企业间的战略整合以及资本市场的支持。 3.1亿美元：Novartis收购IFM Therapeutics的自身免疫部门（2020） 2020年，Novartis收购IFM Therapeutics的自身免疫部门。Novartis以3.1亿美元的价格收购了IFM Therapeutics的自身免疫资产。这些资产包括多个用于治疗自身免疫疾病的小分子药物，旨在通过靶向炎症信号通路来调节免疫反应，极大地增强了Novartis在自身免疫治疗领域的研发能力。 图10：Fierce Biotech网站对此次收购的报道 390亿美元：AstraZeneca收购Alexion Pharmaceuticals（2021） 2021年，AstraZeneca收购Alexion Pharmaceuticals。 AstraZeneca以390亿美元的价格收购了Alexion Pharmaceuticals，这是近年来规模最大的并购案之一。Alexion是开发罕见病和自身免疫疾病治疗药物的领导者，其主要产品Soliris和Ultomiris用于治疗一系列罕见的自身免疫疾病。这次收购使AstraZeneca在免疫学和罕见病领域的地位显著提升。 图11：Pharmaceutical Technology网站对此次并购的报道 自2019年受到COVID-19新冠疫情的影响，资金短缺与市场不确定性、监管审批延误、临床试验停滞、供应链中断、战略优先级变化等多方面的影响和挑战，制药和生物技术行业相关自身免疫疾病领域的并购活动相对减少，但是趋势仍不容忽略。   04   自免并购案屡见不鲜的2024年 让我们目光再转回到2024年，截至五月底，自免相关的并购、收购案例屡见不鲜，并购活动呈现活跃态势。这里聚焦几个比较典型的案例： 2.5亿美元：Novartis收购Calypso Biotech（2024.01） 1月，Novartis以2.5亿美元的价格收购了Calypso Biotech，这家公司开发的CALY-002针对IL-15，用于治疗乳糜泻和嗜酸性食管炎。Novartis计划利用该产品针对多种高未满足需求的自身免疫病适应症进行开发。 图12：European Biotechnology网站关于此次并购的报道 Regeneron收购2seventy Bio的肿瘤和自身免疫资产（2024.04） 4月，Regeneron收购了2seventy Bio的肿瘤和自身免疫资产，并成立了新的研发部门Regeneron Cell Medicine。此次收购包括雇佣了2seventy Bio的160名员工，初步将重点放在CAR-T和CAR-NK疗法的开发上。 图13：Regeneron官网对此次收购的相关内容 Eliem Therapeutics收购Tenet Medicines（2024.04） 同月，Eliem Therapeutics收购了Tenet Medicines，其主要资产是抗CD19抗体TNT119，潜在适应症包括系统性红斑狼疮（SLE）和免疫性血小板减少症等。此次收购使Eliem能够扩展其在自身免疫疾病治疗领域的产品线。 图14：Eliem官网对此次收购的相关内容 强生收购Numab、Ashahi Kasei Corporation收购Calliditas（2024.05） 本文开篇就已经提到，今年5月强生并购Numab，同时五月还有几起自免领域相关的并购案，就在强生并购案的当天，日本化工企业旭化成（Ashahi Kasei Corporation）也宣布准备以10.6亿美元收购瑞典生物技术公司Calliditas Therapeutics，本次收购后，旭化成将获得Calliditas的Nefecon（用以治疗IgA肾病）等。 图15：Ashahi Kasei Corporation公司对本次收购的相关内容   写在最后   随着2024年下半年的到来，预计自身免疫领域的并购活动将继续活跃。 各大生物科技和医药公司将继续通过战略性收购和合作，寻求在自身免疫疾病治疗领域的突破和创新。这些并购活动不仅有助于提升公司在市场上的竞争力，还将加速新疗法的开发和商业化进程，为患者带来更多的治疗选择和希望。 参考资料： [1]强生官网；Numab官网；Amgen官网；AbbVie官网；Sanofi官网；Novartis年报；Regeneron官网；Eliem官网 [2] Switzerland’s Roche Holding Ltd. agreed to buy Syntex Corp. for $5.3 billion [3] Pfizer Bids $82 Billion for Warner-Lambert [4] Amgen's big-ticket play for Immunex [5] Novartis ponies up $310M for IFM Therapeutics’ inflammation-focused unit [6] Novartis AG to buy immunology specialist Calypso Biotech BV [7] J&J to Acquire Rights to Investigational Bispecific Antibody 10.12日，深圳；BiG第二届自免研讨会 8:50-8:55 联合主办方致辞 张  战：卫光控股董事长、卫光生物董事长 8:55-9:00 联合主办方致辞 涂   欢：深圳医学科学院副院长、深圳湾实验室副主任 9:00-9:30 Keynote—炎症免疫检查点与AI驱动药物研发 陈有海：美国医学与生物工程院士、欧洲科学院院士、深圳理工大学药学院院长 9:30-10:00 Keynote—临床视角，创新药开发自免，如何选择适应症？ 徐沪济：海军军医大学长征医院大内科主任兼风湿科主任/清华大学医学院教授 10:00-10:25 MNC视角，AZ在肿瘤+自免的布局和开发策略 章   宇： 阿斯利康产品管线和项目管理副总裁 10:25-10:50 茶歇 10:50-11:40 Panel：自免创新药如何立项？MNC&biotech的布局策略，BD合作背后的故事？ 肖昌春：赛诺菲中国研究负责人、赛诺菲研究院负责人 徐亚南：武田制药全球外部创新合作部中国区负责人 邓天敬：炎明生物联合创始人/CEO 靳照宇：明济生物董事长兼CEO 朱向阳：华奥泰生物总经理 周潇薇：松禾资本董事总经理（主持） 11:40-12:30 Panel：从肿瘤转战自免，创新疗法（CAR-T/CAR- NK/双抗/ADC/PROTAC等）如何选择适应症，不同modality各自开发优势及挑战，在哪里？未来有哪些新靶标值得关注？ 范晓虎：湾岛细胞创始人/CEO 花海清：映恩生物研发副总裁 冯   焱：领泰生物创始人/CEO 张   雷：深圳湾实验室特聘研究员 卢宏韬：科望医药联合创始人/CSO、BiG总干事（主持） 12:30 闭幕致辞&研讨会主持 李  圆：BiG秘书长 12:30-14:00 午餐&参观&自由交流 ● 深圳医学科学院（SMART）、卫光生命科学园、湾有引力（光明生物医药创新中心） 报名入口  PS：免费席位有限，均为审核制 观众门票：0元 含12日自免会议&午餐；限biotech/Pharma、临床、院校科学家、投资机构代表 共建Biomedical创新生态圈！ 如何加入BiG会员？

→ Kristen Mulholland will take over for the retiring Peter Fasolo as chief human resources officer at J&J on Oct. 1. “Peter has led J&J’s talent strategy for the past 16 years including remarkable leadership through the global pandemic and the separation of our consumer health business,” CEO Joaquin Duato said in a statement . “He leaves a legacy of strong leaders, deep bench strength and an inclusive, caring and patient-focused culture.” Fasolo is a Bristol Myers Squibb HR vet who left J&J to become chief talent officer for KKR , only to return in 2010. Mulholland started at J&J in 2005 and has spent nearly five years as head of human resources, global total rewards & enterprise HR functions. → Just do it: Amgen technology chief David Reese said in a LinkedIn post that the pharma giant has appointed Sean Bruich as SVP of artificial intelligence and data. Bruich moves into the pharma world after an 11-year run with Nike , where he vaulted to global VP, insights, data science & analytics. This is the second high-level AI hire by a major pharma in as many weeks — Pfizer just welcomed Berta Rodriguez-Hervas as its new chief AI and analytics officer. → In its biggest personnel news since Doug Williams ’ resignation , Sana Biotechnology has poached Dhaval Patel from UCB as the Seattle biotech awaits data readouts for its CD19-targeted allogeneic CAR-T therapy in a host of indications. Patel had a 10-year career with Novartis before he held the CSO post at UCB for nearly seven years, and he’ll have the same responsibilities at Sana under CEO Steve Harr . Sana said in its second-quarter update that the goal is to reveal data for SC291 in B cell malignancies — and such autoimmune diseases as lupus nephritis, extrarenal lupus and ANCA-associated vasculitis — sometime this year. “His expertise in immunology and autoimmune diseases make[s] him ideally suited to help advance our clinical pipeline,” Harr said in a statement . → Brian Di Donato , the CFO and head of strategy at Immunocore since May 2020 , is stepping down “at the end of the year” to take the CEO job at an unnamed San Diego biotech. Di Donato was the finance leader for Achillion when Alexion scooped it up for $930 million, and he’s also a board member at Jim Wilson joint iECURE , where ex-Achillion chief Joseph Truitt is CEO. → Telix Pharmaceuticals has separated its business into four separate entities: Telix Therapeutics , Telix Precision Medicine (diagnostics), Telix Lightpoint (medtech, from its acquisition of Lightpoint Medical ) and Telix Manufacturing Solutions . With these changes in place, Telix has tapped Richard Valeix as CEO of Telix Therapeutics, Kevin Richardson as Telix Precision Medicine’s chief executive, and Raphael Ortiz as CEO of Telix International . Christian Behrenbruch ’s title has been slightly modified to group CEO. Telix had hoped to join the Nasdaq in June with an IPO around the $200 million mark, but the Melbourne biotech made a gametime decision to pull those plans . → Cambridge, MA-based neuro player Cognito Therapeutics has promoted Christian Howell to CEO. Brent Vaughan had been running Cognito since 2020 after co-founding and leading the autism diagnostic specialist Cognoa , and he hired Howell as his chief commercial officer last October. Howell had a long career with Medtronic and then joined Aetion , where he was elevated to SVP and general manager of the emerging channels group (medical device, diagnostics, digital health, and government) in April 2023. → Elsewhere, Endo is also losing its president and CEO Blaise Coleman . Board member Scott Hirsch will serve in the interim as the company searches for a permanent successor. Hirsch joined Endo’s board in April, around the same time that the company sued the FDA over its approval of a generic version of Endo’s drug Adrenalin . Hirsch is the former CEO of Solta Medical and also held the roles of president of Ortho Dermatologics and CBO of Bausch Health / Bausch + Lomb . → Thomas Bock has handed in his resignation as CEO of Notable Labs , and CSO Joseph Wagner will take over the top spot on an interim basis. This isn’t uncharted territory for Wagner: He’s the former CEO of Oncocyte (2011-15) and Canadian I/O biotech BriaCell Therapeutics (2015-16). Notable Labs merged with VBL Therapeutics in February 2023 and will start enrolling patients in its Phase 2 study of the ex- Boehringer Ingelheim drug volasertib for acute myeloid leukemia “in the coming months,” the company said in July. → Delfi Diagnostics marked the beginning of the year with a new CEO it hired away from Illumina . Now, the competitor to Grail has brought on Thomas Russo as finance chief. Russo served in the same role at Icosavax and Assembly Biosciences . During his time at Icosavax, Russo helped with the company’s growth until its $838 million upfront acquisition by AstraZeneca . → Marea Therapeutics , the Third Rock upstart led by ex- Graphite Bio CEO Josh Lehrer , has selected Ian Clements as CFO. Clements resigned from the same post at Livmarli maker Mirum Pharmaceuticals in May 2023 after four years overall with the company, and he’s the ex-VP of investor relations for Dermira . Marea launched in June with $190 million in “combined Series A and B” funding, testing an ex-Novartis monoclonal antibody that targets ANGPTL4 in adults with metabolic dysfunction. → With ex- Synlogic CEO Aoife Brennan at the controls, a seemingly rejuvenated Eliem Therapeutics has named Brett Kaplan as COO and Nishi Rampal as SVP, clinical development. Kaplan had been president and chief financial & corporate development officer for epigenetic editing upstart Chroma Medicine , and he was also the finance chief at Prevail until Eli Lilly bought the gene therapy biotech for $1 billion. An Alexion vet, Rampal also handled the role of global development and strategy lead for the neuromyelitis optica spectrum disorder (NMOSD) treatment Uplizna as an executive director with Horizon /Amgen. Eliem’s hunt for strategic alternatives ended with the acquisition of Tenet Medicines and its anti-CD19 antibody budoprutug , once known as TNT119 . → Backed by RA Capital and Forbion , Navigator Medicines disclosed its $100 million Series A this week and the recruitment of Dana McClintock as CMO. McClintock spent six years in the same position at Alladapt Immunotherapeutics and was global head of the Office of I2O Innovation for Genentech . Navigator also said that Forbion general partner Wouter Joustra and RA Capital managing director Andrew Levin have made their way to the board of directors. → Alex Bastian has been named VP, commercial strategy at Swiss-based Memo Therapeutics , reuniting with CEO Erik van den Berg . Toward the end of van den Berg’s tenure as CEO of AM-Pharma , Bastian was the Dutch biotech’s VP, commercial & patient access. He also worked for Galapagos as VP, head of value & market access. → Structure Therapeutics , one of many biotechs developing a GLP-1 drug for obesity, has elected ex- Shire CEO Angus Russell to the board of directors. The 68-year-old Russell has chaired the board at Daxxify maker Revance Therapeutics since 2014 and has a board seat at Lineage Cell Therapeutics . → Ex- Vividion CEO Jeff Hatfield has joined the board of directors at Gate Bioscience , a California drug developer that launched last November with a $60 million Series A from several blue-chip investors. Hatfield chairs the board at Vividion and Rome Therapeutics . → Opna Bio has made room for Inozyme co-founder and former CEO Axel Bolte on the board of directors. The South San Francisco biotech also announced that it had dosed the first patient in a Phase 1 trial of its multiple myeloma candidate OPN-6602 and appointed Myeloma Investment Fund managing director Stephanie Oestreich as a board observer.